Massachusetts Institute of Technology

The General Hospital Corporation

Boston University

Whitehead Institute

Innate Biotherapeutics, LLC

Immunexcite, Inc.

Ifat Rubin-Bejerano

Gerald R Fink

Robert Samuel Langer

Gabriel Oscar Reznik

Hua Miao

James Michael Siedlecki

Jason Fuller

John James Kane

Claudia Abeijon

Arthur F Kluge

Eric Steven Furfine

Daniel S Kohane

Robert Langer

Danial S Kohane

Zuzana Dostalova

Isabelle Sansal-Castellano

The present invention encompasses embodiments in which a therapeutic antibody is conjugated to β-1,6-glucan oligomers. Thus, the present invention includes, among other things, compositions including a therapeutic antibody conjugated to one or more β-1,6-glucan oligomers. The present invention further includes, among other things, methods of making and/or using such β-1,6-glucan conjugates. In certain embodiments, a β-1,6-glucan conjugate of the present invention is useful as a therapeutic or in a method of therapy.

ß-1,6-glucan therapeutic antibody conjugates

This invention relates to modifications of &#x3b2;-1,6-D-glucans, e.g., structures according to Formula (I), and the ability of these compositions to modulate an immune response. 

Immunomodulating beta-1,6-D-glucans

This invention is directed to &#x3b2;-1-6-glucans, compositions and devices comprising the same, and methods of use thereof in modulating immune responses. The &#x3b2;-1-6-glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety.

Immunomodulating compositions and methods of use thereof

The invention is directed to &#x3b2;1-6 glucans, compositions, diagnostic kits, and devices comprising the same, and methods of use thereof in modulating immune response and treating, delaying progression of, reducing the incidence or severity of cancer, infection, inflammation, and autoimmune diseases. The &#x3b2;1-6 glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety. The &#x3b2;1-6 glucans of certain embodiments of the invention recruit immunoglobulin G antibodies to mediate complement and neutrophil killing. The conjugated &#x3b2;1-6 glucans of certain embodiments of the invention are targeted to cells to stimulate the immune response at the target location by activating complement-mediated lysis and recruitment of neutrophils.

Immunomodulating compositions and methods of use

Growing community of inventors

Belmont, MA, United States of America

Ifat Rubin-Bejerano